Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Below averageAmneal Pharmaceuticals, Inc. (the “Company”, “we,” “us,” or “our”) is a diversified, global biopharmaceutical company that develops, manufactures, markets, and distributes a diverse portfolio of essential medicines. Our Affordable Medicines segment includes retail generics, injectables, and biosimilars. In our Specialty segment, we offer a portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders.
In the company’s own words · 10-K filed Feb 27, 2026 · SEC EDGAR
Business segments
Jun 2026 · $770.3MThe company’s own SEC segment disclosure.
- Subtotal Therapeutic Classes$149.3M19%
- Central Nervous System$95.3M12%
- Distribution Service$86.9M11%
- Other Dosage Forms$81.6M11%
- Transdermal$67.0M9%
- Ephinephrine Auto Injector$62.2M8%
- Other (9)$227.9M30%
Amneal Pharmaceuticals, Inc. (AMRX) reported revenue of $723M in Q1 2026 (quarter ended Mar 31, 2026), up 3.9% from the same quarter a year earlier. That came with a gross margin of 44% and net income of $62M (8.6% of revenue). For the full year FY2025, revenue was $3.02B (+8.0% year on year) and net income $72M. Its largest product in Jun 2026 was Subtotal Therapeutic Classes at $149M, 19% of the disclosed total, ahead of Central Nervous System at 12%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Drug Manufacturers - Specialty & Generic
Ranks #22 of 29 by Smart Score